SLU-PP-332 Results: What Studies Measured and When
What published studies measured for SLU-PP-332, when those outcomes were measured, and what is still unproven.
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Evidence base is preclinical | The review states clinical trials are needed to confirm efficacy and safety in humans. | Systematic review | Revista medica de Chile 2026, PMID 42024694 |
| Energy expenditure and fatty acid oxidation | In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Fat mass and insulin sensitivity | The ERR agonist reduced obesity and improved insulin sensitivity in mouse models of metabolic syndrome. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Heart failure model | SLU-PP-332 and SLU-PP-915 improved ejection fraction, reduced fibrosis and increased survival in a mouse heart failure model. | Animal · mouse (plus cell experiments) (not a human result) | Circulation 2024, PMID 37961903 |
| Exercise endurance | In mice, SLU-PP-332 increased type IIa oxidative skeletal muscle fibers and enhanced exercise endurance. | Animal · mouse (plus a skeletal muscle cell line) (not a human result) | ACS chemical biology 2023, PMID 36988910 |
| Mitochondrial function in muscle cells | SLU-PP-332 increased mitochondrial function and cellular respiration in a skeletal muscle cell line. | Animal · mouse (plus a skeletal muscle cell line) (not a human result) | ACS chemical biology 2023, PMID 36988910 |
| Aging kidney | An 8-week pan-ERR agonist treatment reversed age-related albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines in aged mice. | Animal · mouse (not a human result) | The American journal of pathology 2023, PMID 37717940 |
| In vitro metabolites | 22 in vitro metabolites were identified; eight (M1, M7, M9, M10, M13, M14, M19, M20) were the most abundant. | In vitro (not a human result) | Drug testing and analysis 2026, PMID 41688415 |
| Myoblast markers and differentiation | In myoblasts from inactive women, SLU-PP-332 down-regulated NOX4 and up-regulated SIRT1, PGC-1α, ERRα, FNDC5, Akt and Bcl-2, reducing oxidative stress and senescence markers. | In vitro (not a human result)n = 20 | Frontiers in physiology 2025, PMID 40692696 |
- No human studies of SLU-PP-332 have been published in PubMed as of 2 October 2026 (10 records, all preclinical, review or analytical chemistry). Everything on this page is mouse or cell data and cannot be read as expected human effects.
- A small Frontiers in Physiology paper (PMID 40692696) used muscle biopsies from 20 women, but SLU-PP-332 was applied only to cultured muscle cells in vitro; the 20 refers to biopsy donors.
- SLU-PP-332 is a small-molecule ERR agonist (not a peptide). It is not FDA-approved, and in the sports context it is covered by WADA's ban on exercise mimetics and metabolic modulators (stated in PMID 41688415).
- No half-life value was found: the sources say only that the compound has 'sufficient pharmacokinetic properties' for in vivo use, and an oral analogue SLU-PP-915 is described because SLU-PP-332 'lacks oral bioavailability' (PMID 41421047).
- No stability data were found.
- Only preclinical data exist for metabolism, weight loss, energy, heart health, longevity and mitochondria. There are no human data for any goal.
Typical timeline
When measurable changes appeared in studies of SLU-PP-332: not reported in study abstracts (PubMed search, 2 Oct 2026).
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Common questions
How long does SLU-PP-332 take to work?
The study abstracts we summarised for SLU-PP-332 do not report when outcomes were measured (PubMed search, 2 Oct 2026).
Do you show SLU-PP-332 before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on SLU-PP-332
DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.PricePrice per mg and per week from dated listings. No vendor links.Half-lifeWhat is measured, by route, and what is not.For weight lossWhat research says about SLU-PP-332 for weight loss.
Sources
- 1[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
- 2A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 3Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Circulation · 2024PMID 37961903Accessed 2 Oct 2026
- 4Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
- 5Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
- 6Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
- 7Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
- 8PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.